European Medicines Agency Approves Label Update for HYQVIA® (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase), Expanding its Use to a Broader Group of Patients with Secondary ImmunodeficienciesBusiness Wire • 09/15/20
Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple MyelomaBusiness Wire • 09/09/20
Presage Announces New, Multi-Project Collaboration with Takeda for Phase 0 Studies of Novel Cancer Agents with CIVO® TechnologyPRNewsWire • 09/09/20
Takeda Joins Lhasa's Effiris Consortium - Powering Model Development Through Privacy-Preserving Data TransferPRNewsWire • 09/08/20
Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USDBusiness Wire • 09/08/20
Blackstone to acquire Takeda's consumer health care business for $2.3 billion: WSJMarket Watch • 08/24/20
Crest View International Comments On Takeda As They Sell Japanese Consumer Health Unit To Blackstone For $2.3 BillionBusiness Wire • 08/24/20
National Hemophilia Foundation and Takeda Partner with Alex Borstein to Raise Awareness of von Willebrand DiseaseBusiness Wire • 08/10/20
Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in JapanGlobeNewsWire • 08/07/20
Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID TrialPRNewsWire • 08/03/20
Takeda to Present Rare Bleeding Disorders Research Highlighting Need for Real-World Evidence at NHF Bleeding Disorders Conference 2020Business Wire • 08/01/20
Takeda Pharmaceutical Co Ltd (TAK) CEO Christophe Weber on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/01/20
Takeda Announces FY2020 Q1 Results; Confirms Management Guidance & Raises Reported Operating Profit And Reported Net Profit for the Full YearBusiness Wire • 07/31/20
Takeda's Entyvio and Janssen's Stelara Share of Inflammatory Bowel Disease Biologic-Naive Patients Continues to Increase as This Patient Group Expands Their Involvement in the Decision-Making ProcessPRNewsWire • 07/30/20
Takeda Announces U.S. FDA Breakthrough Therapy Designation Granted for Pevonedistat for the Treatment of Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS)Business Wire • 07/30/20